LINC00474: A Potential Drug Target for Cancer, Autoimmune Disorders and Neurodegenerative Diseases

Target Name: LINC00474

NCBI ID: G58483

LINC00474

LINC00474: A Potential Drug Target for Cancer, Autoimmune Disorders and Neurodegenerative Diseases

LINC00474 (EST-YD1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell antigen receptor (TCR) family, which is a protein that is involved in the immune response. LINC00474 is also known as ITCH2, and it is a potential drug target (or biomarker) for several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

The ITCH2 gene is located on chromosome 16, and it encodes a protein that is composed of 256 amino acids. The protein has a molecular weight of 35.1 kDa, and it has four known functions:

1. Intercellular signaling: LINC00474 is involved in intercellular signaling, which is the process by which cells communicate with each other. It is a negative regulator of the transcription factor NKD3, which is involved in the development and maintenance of tissues. LINC00474 helps to prevent NKD3 from activating, which can lead to the formation of cancerous tumors.

2. Cell adhesion: LINC00474 is involved in cell adhesion, which is the process by which cells stick together to form tissues and organs. It is a critical regulator of cell adhesion, and it helps to maintain the integrity of tissues.

3. Neuronal function: LINC00474 is involved in neuronal function, which is the process by which the brain and nervous system function. It is a critical regulator of neuronal excitability, and it helps to maintain the normal function of the brain.

4. Immune response: LINC00474 is involved in the immune response, which is the process by which the body defends itself against foreign substances, such as viruses and bacteria. It is a critical regulator of the immune response, and it helps to ensure that the The body is able to fight off infections and diseases.

Due to its involvement in these processes, LINC00474 has been identified as a potential drug target (or biomarker) for several diseases. For example, LINC00474 has been shown to be involved in the development and progression of cancer, including breast cancer and lung cancer. It has also been shown to be involved in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Additionally, LINC00474 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In conclusion, LINC00474 is a protein that is involved in several important processes in the body, including intercellular signaling, cell adhesion, neuronal function, and the immune response. As a result, it has been identified as a potential drug target (or biomarker) for several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Further research is needed to fully understand the role of LINC00474 in these processes, and to determine the most effective way to use it as a therapeutic agent.

Protein Name: Long Intergenic Non-protein Coding RNA 474

The "LINC00474 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00474 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets